Monoklonaalsed antikehad (L01XC), immuunosupressandid (L04), omalizumab (R03DX05), mepolizumab (R03DX09), benraluzumab (R03DX10)

Integrity Indicators

4 out of 4

Has multiple bidders
No disputes from bidders or outsiders
Sellers have not recently made any political party donations
Bidding period is adequate

Estimated Cost

Actual Cost

Duration

43 days

Bidders

6 bidders

Bids

6 bids

Disputes

0 disputes

Process Type	Open procedure
Offers Revealed At	Jan 4, 2019 11:00am

Showing board-level people associated with the buyer and seller organizations 12 months prior up to 12 months after the procurement process. Also shown are their political affiliations and donations within the same period.

Contracts

Roche Eesti Osaühing 1. Roche Eesti OÜ Signed Feb 13, 2019 with completion deadline Feb 1, 2020.	€7.94M est. €7.94M
TAMRO EESTI OÜ 2. Tamro Eesti OÜ Signed Feb 15, 2019 with completion deadline Feb 1, 2020.	€1.97M est. €1.97M
Osaühing Baltfarma 3. Baltfarma OÜ Signed Feb 13, 2019 with completion deadline Feb 1, 2020.	€361,897 est. €361,897
MAGNUM MEDICAL OÜ 4. Magnum Medical OÜ Signed Feb 13, 2019 with completion deadline Feb 1, 2020.	€3.33M est. €3.33M
MAGNUM MEDICAL OÜ 5. Magnum Medical OÜ/Pärnu Haigla Signed Mar 4, 2019 with completion deadline Feb 1, 2020.	€199,530 est. €199,530
Osaühing Baltfarma 6. Baltfarma/Pärnu Haigla Signed Mar 5, 2019 with completion deadline Feb 1, 2020.	€44,014^.50 est. €44,014^.50
TAMRO EESTI OÜ 7. Tamro Eesti/ Pärnu Haigla Signed Mar 5, 2019 with completion deadline Feb 1, 2020.	€175,779 est. €175,779
Roche Eesti Osaühing 8. Roche Eesti OÜ/Pärnu Haigla Signed Mar 8, 2019 with completion deadline Feb 1, 2020.	€348,421 est. €348,421